SCHEMBL10063807

SCHEMBL10063807

CC[C@H](C)[C@H](OCc1ccccc1)[C@H]1[C@H]([N+](=O)[O-])[C@H](c2ccccc2)N[C@@H]1C(=O)NCCCCCC(=O)NO

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ITGAL P20701 2/20 0.57
HDAC2 Q92769 14/20 0.39
HDAC1 Q13547 12/20 0.39
HDAC6 Q9UBN7 12/20 0.39
HDAC3 O15379 11/20 0.39
HDAC8 Q9BY41 11/20 0.39
HDAC10 Q969S8 10/20 0.39
HDAC11 Q96DB2 10/20 0.39
HDAC4 P56524 9/20 0.39
HDAC7 Q8WUI4 9/20 0.39
HDAC9 Q9UKV0 9/20 0.39
HDAC5 Q9UQL6 9/20 0.39
NCOR2 Q9Y618 2/20 0.35
GAA P10253 1/20 0.34
KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4638326 0.93 ITGAL (0.63) ITGALGAA
SCHEMBL1777466 0.93 ITGAL (0.63) ITGALGAA
SCHEMBL1777467 0.93 ITGAL (0.63) ITGALGAA
SCHEMBL1777642 0.92 ITGAL (0.56) ITGALGAA
SCHEMBL1777643 0.92 ITGAL (0.56) ITGALGAA
SCHEMBL4639092 0.92 ITGAL (0.56) ITGALGAA
SCHEMBL4637570 0.92 ITGAL (0.64) ITGALGAA
SCHEMBL1777060 0.92 ITGAL (0.64) ITGALGAA
SCHEMBL1777058 0.92 ITGAL (0.64) ITGALGAA
SCHEMBL4639099 0.90 ITGAL (0.67) ITGALGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1975158-B9 NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY UNIV PAIS VASCO (ES) 2012-02-29 EP disclosed
EP-1975158-B1 NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY UNIV PAIS VASCO (ES) 2011-07-13 EP disclosed
US-7638550-B2 new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) 2009-12-29 US disclosed
US-7638550-B2 new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) 2009-12-29 US disclosed
US-20080262073-A1 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) 2008-10-23 US disclosed
US-20080262073-A1 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) 2008-10-23 US disclosed
EP-1975158-A1 NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) 2008-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262073-A1 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity HDAC1, HDAC11, HDAC5 ITGAL 3453/4885HDAC2 4/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.